GLP1R and diabetes mellitus: In a retrospective study including 920 patients, Israelsen et al. showed that neither current use (defined as redeemed prescriptions within 90 days before testing positive for SARS-CoV-2) of GLP-1 RA nor DPP-4i were associated with improved outcomes of individuals with diabetes infected with SARS-CoV-2 when compared with SGLT-2i use.